News & Updates
Filter by Specialty:
Antidepressant therapy: To continue or not?
In individuals who had been on antidepressant therapy for at least 9 months but felt well enough to consider discontinuing, the risk of relapse of depression was greater among those who stopped vs those who carried on with their current regimen, the ANTLER* trial has shown.
Antidepressant therapy: To continue or not?
14 Dec 2021Is prior allergy a deal-breaker for COVID-19 vacc?
A large prospective, observational study has suggested that while individuals with a history of high-risk allergy may have an increased risk of allergic reactions following receipt of a messenger RNA (mRNA) COVID-19 vaccine, they are still able to receive both vaccine doses.
Is prior allergy a deal-breaker for COVID-19 vacc?
13 Dec 2021Opioid medication linked to patients’ familiarity, perceptions of efficacy
Use of opioid among adults with knee and/or hip osteoarthritis (OA) often leads to being familiar with the treatment and believing that the medication is beneficial and low-risk, reveals a recent study.
Opioid medication linked to patients’ familiarity, perceptions of efficacy
13 Dec 2021Can losartan delay the progression of AD?
In individuals with clinically diagnosed mild-to-moderate Alzheimer’s disease (AD), treatment with the angiotensin II receptor blocker (ARB) losartan for 12 months did not reduce the rate of brain atrophy, findings from the phase II RADAR* trial suggest.
Can losartan delay the progression of AD?
13 Dec 2021Cutting first-day dexamethasone dose not recommended for breast cancer patients on anthracycline
In breast cancer patients treated with anthracycline-containing regimens, reducing the first-day dose of dexamethasone does not yield significant gastrointestinal benefit and is not recommended for nausea management, a recent study has found.
Cutting first-day dexamethasone dose not recommended for breast cancer patients on anthracycline
11 Dec 2021Sildenafil efficacy, safety sustained regardless of delivery method
Sildenafil orally disintegrating strips (ODS) are just as effective and safe as the conventional tablet formulation for the treatment of erectile dysfunction (ED), a Thai study suggests.